Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.14 USD

28.14
31,748,940

-0.57 (-1.99%)

Updated Aug 16, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Corcept Therapeutics Focuses on Korlym's Label Expansion

by Zacks Equity Research

We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.

    Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

    by Zacks Equity Research

    We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

      Pfizer's Mylotarg Recommended by FDA Advisory Committee

      by Zacks Equity Research

      Pfizer Inc. (PFE) announced that the FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

        Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

        by Zacks Equity Research

        Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

          J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?

          by Zacks Equity Research

          Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.

            Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

            by Zacks Equity Research

            Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

              Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

              by Zacks Equity Research

              Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

                Lilly's Breast Cancer Drug Gets Priority Review Status by FDA

                by Zacks Equity Research

                Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.

                  Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

                  by Zacks Equity Research

                  Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

                    by Arpita Dutt

                    3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

                      Pfizer's (PFE) Leukemia Candidate Receives Approval in EU

                      by Zacks Equity Research

                      Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.

                        Why is Corcept's Stock Up More Than 60% So Far This Year?

                        by Zacks Equity Research

                        Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.

                          Arena Ends Study on Extended Release Formulation of PAH Drug

                          by Zacks Equity Research

                          Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

                            Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

                            by Zacks Equity Research

                            We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

                              Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                              by Zacks Equity Research

                              Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                                Arpita Dutt headshot

                                M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

                                by Arpita Dutt

                                The biotech sector's fundamentals remain strong.

                                  Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

                                  by Zacks Equity Research

                                  Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

                                    AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use

                                    by Zacks Equity Research

                                    AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.

                                      Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                                      by Zacks Equity Research

                                      Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                                        Epizyme Progressing Well on Two Lead Pipeline Candidates

                                        by Zacks Equity Research

                                        We issued an updated research report on Epizyme, Inc. (EPZM) on Jun 23, 2017.

                                          Eric Dutram headshot

                                          Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

                                          by Eric Dutram

                                          This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!

                                            Stock Market News for June 22, 2017

                                            by Zacks Equity Research

                                            Energy shares continued to decline on Wednesday, sending the Dow and the S&P 500 lower

                                              Merck's Keytruda on a Roll: Can it Retain the Momentum?

                                              by Zacks Equity Research

                                              As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.

                                                Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

                                                by Zacks Equity Research

                                                Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

                                                  Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More

                                                  by Zacks Equity Research

                                                  The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.